KR102033260B1 - Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same - Google Patents
Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same Download PDFInfo
- Publication number
- KR102033260B1 KR102033260B1 KR1020180166310A KR20180166310A KR102033260B1 KR 102033260 B1 KR102033260 B1 KR 102033260B1 KR 1020180166310 A KR1020180166310 A KR 1020180166310A KR 20180166310 A KR20180166310 A KR 20180166310A KR 102033260 B1 KR102033260 B1 KR 102033260B1
- Authority
- KR
- South Korea
- Prior art keywords
- seaweed
- fine dust
- weight
- extract
- food
- Prior art date
Links
- 239000000428 dust Substances 0.000 title claims abstract description 67
- 235000013305 food Nutrition 0.000 title claims abstract description 39
- 239000000284 extract Substances 0.000 title claims abstract description 32
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 32
- 241001474374 Blennius Species 0.000 title claims description 108
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000032683 aging Effects 0.000 claims abstract description 8
- 239000000419 plant extract Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241000196324 Embryophyta Species 0.000 claims description 25
- 210000005069 ears Anatomy 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 23
- 230000000638 stimulation Effects 0.000 claims description 22
- 240000000599 Lentinula edodes Species 0.000 claims description 17
- 241000218691 Cupressaceae Species 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 238000010257 thawing Methods 0.000 claims description 11
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 241000190633 Cordyceps Species 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- 206010033546 Pallor Diseases 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 abstract description 9
- 238000012545 processing Methods 0.000 abstract description 9
- 241001261506 Undaria pinnatifida Species 0.000 abstract description 7
- 235000019629 palatability Nutrition 0.000 abstract description 7
- 235000013311 vegetables Nutrition 0.000 abstract 2
- 239000000047 product Substances 0.000 description 24
- 238000000855 fermentation Methods 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 15
- 239000000126 substance Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 206010006451 bronchitis Diseases 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005070 ripening Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- -1 analgesic Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241000332371 Abutilon x hybridum Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-KKQCNMDGSA-N (2r,3r,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-KKQCNMDGSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000186321 Cellulomonas Species 0.000 description 1
- 241000186221 Cellulosimicrobium cellulans Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000723436 Chamaecyparis obtusa Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 1
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000252132 Pleurotus eryngii Species 0.000 description 1
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 244000285940 beete Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000011222 chang cao shi Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 241000512250 phototrophic bacterium Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 108010075550 termamyl Proteins 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003403 water pollutant Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 미역귀를 포함하는 미세먼지 자극 호흡기 질환 개선용 식품 및 그의 제조 방법에 관한 것으로서, 좀 더 상세하게는 미역귀를 가공 처리한 후 이를 혼합 식물 추출액에 침지 및 숙성시켜서 제조함으로서 제품의 기능성 및 기호성이 배가된 특성을 갖는 미역귀를 포함하는 미세먼지 자극 호흡기 질환 개선용 식품 및 그의 제조 방법에 관한 것이다.The present invention relates to foods for improving fine dust stimulation respiratory disease, including seaweed ears, and more particularly, a method for producing and processing the seaweed ears and then immersing and ripening them in a mixed plant extract, the functionality and palatability of the product The present invention relates to a food for improving fine dust-stimulated respiratory disease and a method for producing the same, including seaweed ears having this doubled property.
우리나라는 지난 수십 년간 급격한 산업화 및 공업화와 도시 집중화로 인해 환경이 지속적으로 악화되어 왔으며, 특히 대도시의 환경오염은 심각한 실정임. 천연연료 사용의 공급확대 등의 환경 정책과 오염물질 규제 강화로 인해 SO2, CO, 부유 분진 농도는 점차 감소하고 있지만, 자동차의 급격한 증가로 인하여 미세먼지, 오존, 질소산화물, 탄화수소물의 오염물질은 오히려 증가하는 경향을 보이고 있다.In Korea, the environment has been continuously deteriorated due to rapid industrialization, industrialization and urban concentration over the last few decades. In particular, environmental pollution in large cities is serious. Due to environmental policy enhanced regulation contaminants such as supply-up of the use of natural fuel SO 2, CO, floating dust concentration, but is gradually decreased, due to the rapid increase in the car fine dust, ozone, nitrogen oxides, hydrocarbons water pollutant Rather, it is increasing.
또한, 중국의 석탄 의존도가 70% 이상으로 높아 스모그 현상이 지속적 증가하고, 몽고 건조지대에서 발생한 황사와 스모그, 고농도 먼지들이 합쳐져서 미세먼지의 발생 및 증가가 예상된다.In addition, China's dependence on coal is more than 70%, so the smog phenomenon continues to increase, and fine dust is expected to occur due to the combination of yellow dust, smog, and high-density dust from Mongolia.
미세입자는 황산화물, 질소산화물, 납, 오존, 일산화탄소 등의 매우 복잡한 성분을 가진 대기 중에서 부유하고 있는 물질이며, 대부분 자동차 배기가스, 도로의 먼지 등으로부터 발생하는 것으로 알려져 있다.Fine particles are substances suspended in the atmosphere having very complex components such as sulfur oxides, nitrogen oxides, lead, ozone, and carbon monoxide, and are known to be mostly generated from automobile exhaust gas and road dust.
미세먼지의 크기와 성분은 매우 복잡하고 다양한데, PM10은 입경(공기역학적 직경) 10㎛ 이하의 미세먼지라 불리고, PM2.5는 입경 2.5㎛ 이하의 초미세먼지라 불리며, PM1.0은 입경 1.0㎛ 이하의 미세한 먼지이며, 입자의 크기, 표면적, 화학적 조성이 건강영향을 결정하는 것으로 알려져 있다.The size and composition of fine dust are very complex and diverse, PM10 is called fine dust with particle size (aerodynamic diameter) of 10㎛ or less, PM2.5 is called ultra fine dust with particle size of 2.5㎛ or less, and PM1.0 is particle size 1.0 It is a fine dust of less than or equal to μm, and the particle size, surface area, and chemical composition are known to determine health effects.
미세먼지의 호흡기 영향은 주로 세기관지에서 염증반응을 일으킴으로써 발생하는데, 이러한 작용은 천식, 만성기관지염, 기도폐쇄 등을 일으키거나 악화시키는 작용을 하게 된다.Respiratory effects of fine dust are mainly caused by inflammatory reactions in the bronchioles, such action is to cause or worsen asthma, chronic bronchitis, airway obstruction.
또한, 미세먼지는 폐 조직에서 박테리아의 불활성화 혹은 제거 작용을 방해함으로써 호흡기계 감염을 일으킬 수도 있으며, 최근에는 미세먼지가 심근경색, 뇌졸중, 심박동수 이상, 급사 등과 같은 심혈관계질환의 중요한 위험요인으로 받아들여지고 있다.In addition, fine dust may cause respiratory infections by interfering with the inactivation or removal of bacteria in lung tissue. Recently, fine dust is an important risk factor for cardiovascular diseases such as myocardial infarction, stroke, heart rate abnormality and sudden death. It is accepted.
미세먼지의 노출은 호흡기 및 심혈관계 질환의 발생뿐만 아니라 사망률의 증가와도 관련이 있는 것으로 보고되고 있으며, 연령대별로 보면 신체적으로 면역력이 약한 취학 전 아동과 70대 이상 노인층에서 미세먼지 및 황사의 영향이 더 큰 것으로 나타났다.Exposure to fine dust is associated with increased mortality as well as incidence of respiratory and cardiovascular diseases. By age group, the effects of fine dust and yellow dust in preschool children with physically weak immunity and elderly people over 70 This turned out to be bigger.
미세먼지에 의한 호흡기 질환으로는 감기, 기관지염, 폐렴, 결핵, 폐암 및 만성기관지염 등이 대표적이다. 감기는 모든 연령층에서 콧물과 코막힘이 급작스럽게 발생되는 질환이며, 기관지염은 상기도에 바이러스감염이 생기면 하기도까지 바이러스가 파급되어 급성기관지염이 되며, 결핵은 결핵균의 감염에 의해 생기는 감염성 질환이며, 폐렴은 폐조직에 발생하는 염증성 질환이며, 만성기관지염은 모세 기관지의 염증으로 기관지 점막이 섬유성 염증반응으로 좁아지게 되고 점막세포로부터 점액의 분비가 많아져 기도가 폐쇄되는 질환을 말한다.Respiratory diseases caused by fine dust include cold, bronchitis, pneumonia, tuberculosis, lung cancer and chronic bronchitis. A common cold is a runny nose and stuffy nose in all age groups. Bronchitis is a viral bronchitis that spreads to the lower airway when a viral infection occurs in the upper respiratory tract. Tuberculosis is an infectious disease caused by the infection of Mycobacterium tuberculosis. Chronic bronchitis refers to a disease in which the bronchial mucosa becomes narrow due to fibrotic inflammatory reactions due to the inflammation of the capillary bronchus and the secretion of mucus from the mucosal cells increases, causing airway obstruction.
따라서, 천연물의 유익한 성분들을 이용하여 기능성 식품 등을 제공함으로써 이러한 미세먼지에 의해 야기되는 질환을 예방하고 개선할 필요가 있다.Therefore, there is a need to prevent and ameliorate diseases caused by such fine dust by providing functional foods and the like using the beneficial ingredients of natural products.
본 발명자들은 천연물을 이용하여 미세먼지에 효율적인 성분들을 탐색하여 유용한 제품을 개발하기 위하여 예의 연구한 결과, 후술하는 바와 같이 미역귀를 가공 처리한 후 이를 혼합 식물 추출액에 침지 및 숙성시켜서 제조한 식품이 미세먼지에 의해 유발된 호흡기 질환을 개선시키는 기능성과 기호성이 개선된 결과를 초래함으써 이를 요하는 환자나 소비자에게 유용하게 이용될 수 있음을 발견하고 본 발명을 완성하기에 이르렀다.The present inventors have diligently researched to develop useful products by searching for components effective for fine dust using natural products. As a result, the food produced by processing seaweed ear as described below and then immersing and ripening them in a mixed plant extract is fine. The present invention has been accomplished by discovering that it can be usefully used for patients or consumers who need it by improving the functionality and palatability of improving respiratory diseases caused by dust.
따라서, 본 발명의 목적은, 일면에 있어서,Therefore, an object of the present invention, in one aspect,
미역귀를 가공 처리한 후 이를 혼합 식물 추출액에 침지 및 숙성시켜서 제조함으로써 미세먼지에 의해 유발된 호흡기 질환을 개선시키는 기능성과 기호성이 개선된 미역귀를 포함하는 미세먼지 자극 호흡기 질환 개선용 식품 및 그의 제조 방법을 제공하는 데에 있다.Foods for improving fine dust stimulation respiratory diseases, including seaweed ears with improved functionality and palatability to improve respiratory diseases caused by fine dust by processing the seaweed ears and then immersing and ripening them in a mixed plant extract; To provide.
위와 같은 본 발명의 목적은The object of the present invention as described above
a) 채취한 미역귀를 전처리하는 단계;a) pretreatment of the collected seaweed;
b) 전처리된 미역귀를 -30 ~ -40℃까지 동결시키는 단계;b) freezing the pretreated seaweed to −30 to −40 ° C .;
c) 동결된 미역귀를 세척수에 담궈서 해동시키는 단계;c) thawing by immersing the frozen seaweed in wash water;
d) 상기 해동과 동시에 미역귀에 공기를 분사하여 세척하는 단계;d) spraying and washing air into seaweed at the same time as the thawing;
e) 상기 세척수 및 이에 포함된 이물질을 제거하여 미역귀를 선별하는 단계;e) screening seaweed ears by removing the washing water and foreign matter contained therein;
f) 미역귀에 세척수를 공급하여 2차 세척하는 단계;f) supplying the wash water to seaweed ears to perform the second washing;
g) 세척된 미역귀를 일정 크기로 커팅하는 단계;g) cutting the washed seaweed into a certain size;
h) 커팅된 미역귀를 데치는 단계;h) blanching the cut seaweed;
i) 데친 미역귀 슬라이스를 냉각시키는 단계;i) cooling the poached seaweed slice;
j) 냉각된 미역귀 슬라이스를 복합 식물 추출액 중에 침지시켜 발효 및 숙성시키는 단계;j) fermenting and aging by immersing the cooled seaweed slice in a complex plant extract;
k) 숙성이 완료된 미역귀 및 복합 식물 추출액을 일정 단위의 제품으로 포장하는 단계; 및k) packaging the seaweed and complex plant extracts which have been matured into a unit of product; And
l) 포장된 제품을 멸균하는 단계;를 포함하고,l) sterilizing the packaged product;
상기 복합 식물 추출액은 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 혼합 식물을 추출하여 제조된 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법에 의해 달성될 수 있다.The complex plant extract is to be achieved by a method for producing a food for the improvement of fine dust stimulation respiratory disease, characterized in that it is produced by extracting a mixed plant comprising seaweed, shiitake mushroom or millilis cordyceps sinensis, gilyeong, windproof and cypress Can be.
본 발명에 의한 미세먼지 자극 호흡기 질환 개선용 식품 및 그의 제조 방법에 따르면 미역귀를 가공 처리한 후 이를 혼합 식물 추출액에 침지 및 숙성시켜서 제조함으로써 미세먼지에 의해 유발된 호흡기 질환을 개선시키는 기능성과 기호성이 개선되어 이를 예방하거나 개선하기 위한 기능성 식품으로 유용하게 이용될 수 있다.According to the present invention for improving the fine dust stimulation respiratory disease and a method for producing the same, the processing and processing of seaweed ears and then immersing and ripening them in a mixed plant extract to improve the functionality and palatability of the respiratory disease caused by fine dust It can be usefully used as a functional food to improve or prevent it.
도 1은 본 발명의 미역귀를 포함하는 미세먼지 자극 호흡기 개선 질환의 개선용 식품의 제조 방법의 제조 공정도이다.
도 2는 미역귀 및 혼합 식물 추출 제품의 미세먼지 유발 지질 과산화 억제 결과를 나타내는 그라프도이다.
도 3은 미역귀 제품의 Raw264.7 세포주에 대한 PM-유발 세포 치사의 보호에 미치는 영향을 나타낸 그라프도이다.1 is a manufacturing process diagram of a method for producing a food for the improvement of micro-dust stimulation respiratory disease comprising the seaweed of the invention.
Figure 2 is a graph showing the results of inhibition of fine dust-induced lipid peroxidation of seaweed and mixed plant extracts.
Figure 3 is a graph showing the effect on protection of PM-induced cell death against Raw264.7 cell line of seaweed products.
본 발명은, 일면에 있어서, In one aspect, the present invention,
a) 채취한 미역귀를 전처리하는 단계;a) pretreatment of the collected seaweed;
b) 전처리된 미역귀를 -30 ~ -40℃까지 동결시키는 단계;b) freezing the pretreated seaweed to −30 to −40 ° C .;
c) 동결된 미역귀를 세척수에 담궈서 해동시키는 단계;c) thawing by immersing the frozen seaweed in wash water;
d) 상기 해동과 동시에 미역귀에 공기를 분사하여 세척하는 단계;d) spraying and washing air into seaweed at the same time as the thawing;
e) 상기 세척수 및 이에 포함된 이물질을 제거하여 미역귀를 선별하는 단계;e) screening seaweed ears by removing the washing water and foreign matter contained therein;
f) 미역귀에 세척수를 공급하여 2차 세척하는 단계;f) supplying the wash water to seaweed ears to perform the second washing;
g) 세척된 미역귀를 일정 크기로 커팅하는 단계;g) cutting the washed seaweed into a certain size;
h) 커팅된 미역귀를 데치는 단계;h) blanching the cut seaweed;
i) 데친 미역귀 슬라이스를 냉각시키는 단계;i) cooling the poached seaweed slice;
j) 냉각된 미역귀 슬라이스를 복합 식물 추출액 중에 침지시켜 발효 및 숙성시키는 단계;j) fermenting and aging by immersing the cooled seaweed slice in a complex plant extract;
k) 숙성이 완료된 미역귀 및 복합 식물 추출액을 일정 단위의 제품으로 포장하는 단계; 및k) packaging the seaweed and complex plant extracts which have been matured into a unit of product; And
l) 포장된 제품을 멸균하는 단계;를 포함하고,l) sterilizing the packaged product;
상기 복합 식물 추출액은 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍 및 편백 을 포함하는 혼합 식물을 추출하여 제조된 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법을 제공한다.The complex plant extract provides a method for producing a food for improving the fine dust irritation respiratory disease, characterized in that the extract is prepared by extracting a mixed plant, including seaweed, shiitake mushroom or militaris Cordyceps sinensis, gilyeong, windproof and cypress.
본 발명은, 추가의 일면에 있어서, In another aspect, the present invention,
상기 복합 식물 추출액은The complex plant extract is
j1) 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 식물을 개별적으로 전처리하는 단계;j1) individually pretreatment of plants including seaweed, shiitake mushrooms or militaris cordyceps, gilyeong, windproof and cypress;
j2) 전처리된 식물을 건조시키는 단계;j2) drying the pretreated plant;
j3) 건조된 미역귀 40~60 중량%, 표고버섯 또는 밀리타리스 동충하초 15~30%, 길경 15~30 중량%, 방풍 5~12중량% 및 편백 3~10중량%의 비율로 혼합하는 단계;j3) mixing the dried
j4) 혼합된 식물에 중량을 기준으로 5~25배수의 용매를 가하여 0.5~0.6 기압 및 60~80℃의 온도에서 7 내지 48시간 동안 1차 추출하여 추출물을 얻는 공정;j4) adding a solvent of 5 to 25 times the weight of the mixed plant by weight to obtain a extract by primary extraction for 7 to 48 hours at 0.5 to 0.6 atm and a temperature of 60 to 80 ℃;
j5) 얻어진 추출물을 여과하여 이물질을 걸러내는 단계;j5) filtering the obtained extract to filter foreign matter;
j6) 이물질을 걸러내고 남은 고형분에 중량을 기준으로 5~25배수의 용매를 가하여 0.8~0.9 기압 및 80~95℃의 온도에서 3 내지 24시간 동안 2차 추출하여 추출물을 얻는 단계;j6) filtering foreign matter and adding 5 to 25 times the solvent by weight to the remaining solids to obtain an extract for 2 to 3 hours at 0.8 to 0.9 atm and a temperature of 80 to 95 ° C. for extraction;
j7) 얻어진 추출물을 여과하여 이물질을 걸러내는 단계;j7) filtering the obtained extract to filter foreign matter;
j8) 상기 1, 2차 추출에 의해 얻어진 추출물을 합한 후 50~65℃의 온도에서 -0.08 ~ -0.09 MPA의 감압하에서 4~8시간 동안 고형분의 brix°가 40 이상이 되게 농축하는 단계;에 의해 제조되는 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법을 제공한다.j8) combining the extracts obtained by the first and second extraction and concentrating the brix ° of solids to 40 or more for 4 to 8 hours under a reduced pressure of -0.08 to -0.09 MPA at a temperature of 50 to 65 ° C; It provides a method for producing a food for the improvement of fine dust stimulation respiratory disease characterized in that it is produced by.
본 발명은, 다른 추가의 일면에 있어서,In another further aspect of the present invention,
상기 추출 공정에서 추출 용매로는 물, 주정, 메탄올 및 에탄올로 이루어진 군 중에서 선택되는 하나 이상인 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법을 제공한다.In the extraction process, the extraction solvent provides water, alcohol, methanol and ethanol provides a method for producing a food for improving the fine dust stimulation respiratory disease, characterized in that at least one selected from the group consisting of.
본 발명은 다른 추가의 일면에 있어서,In yet another aspect, the present invention,
전술한 방법에 의해 제조되는 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품을 제공한다.It provides a food for the improvement of fine dust stimulation respiratory disease characterized in that it is produced by the above-described method.
이하, 본 발명에 따른 미역귀를 포함하는 미세먼지 자극 호흡기 질환의 개선용 식품 및 그의 제조 방법에 관하여 첨부된 도면을 참고하여 더욱 상세하게 설명한다. Hereinafter, with reference to the accompanying drawings, the food for improving the fine dust stimulation respiratory disease, including the seaweed ear according to the present invention and a manufacturing method thereof will be described in more detail.
이하, 본 발명에 사용되는 주요 재료에 관하여 설명한다.Hereinafter, the main material used for this invention is demonstrated.
미역귀는 갈조류의 곤포과에 속하는 1년생 해조류로서 칼슘, 칼륨, 철분, 요오드 등의 무기질 성분 및 생리활성 성분을 함유하고 있고, 특히 점질물과 다당류는 농약 등으로 오염된 식품 중의 중금속을 흡착 배설하는 효과가 있으며 갈조류 세포막의 중요 구성성분인 alginic acid는 D-mannuronic acid와 L-glucuronic acid의 혼성중합체로 콜레스테롤 배출작용 및 Cd, Sr의 체내 흡수억제와 정장작용이 있는 것으로 보고되었다.Seaweed ear is a year-old seaweed belonging to the balsam family of brown algae, and contains minerals and physiologically active ingredients such as calcium, potassium, iron, and iodine. Especially, the viscous substance and polysaccharide have the effect of absorbing and excreting heavy metals from food contaminated with pesticides. In addition, alginic acid, an important component of brown algae cell membrane, is a copolymer of D-mannuronic acid and L-glucuronic acid.
표고버섯(Lentinus edodes)은 참나무 등 활엽수에 기생하는 담자균류 주름버섯목 느타리과에 속하며 향미성분과 약리효과를 가지고 있어 국내에서도 식용 및 약용으로 널리 이용되고 있다.Shiitake mushrooms (Lentinus edodes) belongs to the genus Pleurotus eryngii, which is a parasitic fungi parasitic in hardwoods such as oak trees. It has a flavor and pharmacological effect and is widely used for food and medicinal purposes in Korea.
표고버섯 추출물은 식품의약품안전처 기준 건강기능식품 고시형 원료로 등재되어 있으나, 위 소재에 대한 호흡기보호 효과에 대한 자료는 없는 상황이다.Shiitake mushroom extract is listed as a food supplement for health functional food standard by the Ministry of Food and Drug Safety, but there is no data on the respiratory protection effect on the above material.
동충하초는 산삼, 녹용과 함께 3대 한약재로 전 세계적으로 약 300여종이 분포하며, 우리나라에서는 약 80여종이 자생한다. 이 중 밀리타리스동충하초(Cordyceps militaris)는 항균활성을 나타내는 코디셉틴(Cordycepin) 등 생체 기능 조절물질을 함유하고 있는 것으로 보고되었으며, 또한 항비만, 항알러지, 간기능 개선효과 등의 효능이 입증되면서 기능성 식품, 건강보조 식품, 신약 등의 소재로 각광을 받고 있다.Cordyceps sinensis, along with wild ginseng and deer antler, is one of the three major medicinal herbs around the world, and about 300 species are distributed around the world. Among them, Cordyceps militaris has been reported to contain biomodulators such as Cordycepin, which exhibits antimicrobial activity, and also has been shown to be effective in improving anti-obesity, anti-allergy and liver function. It is attracting attention as a material for functional foods, health supplement foods, and new drugs.
그러나, 밀리타리스동충하초의 야생 자실체 수량은 한정되어 있으며, 살아 있는 곤충에서의 경제성 있는 인공재배 방법이 개발되지 않아 식물성 재료인 현미를 이용하여 제한적으로 생산되고 있다. 살아있는 곤충 기주에서 생산된 밀리타리스동충하초는 자연에서의 동충하초 발생원리와 매우 유사하게 생체대사과정을 거쳐 발생되므로 보다 풍부한 기능성 물질이 함유된 것으로 보고되었다. 즉 버섯에 해당하는 자실체에는 항비만, 항알러지, 간기능 개선효과 등이 우수한 물질이 풍부하며, 기주인 번데기에는 면역증강물질이 다량 함유되어 있다.However, the number of wild fruiting bodies of Militaris cordyceps is limited, and economical artificial cultivation methods for live insects have not been developed, and therefore, they are limitedly produced using brown rice, which is a vegetable material. Militaris cordyceps, produced on living insect hosts, has been reported to contain abundant functional substances because it occurs through metabolic processes very similar to the principle of cordyceps in nature. In other words, the fruiting body corresponding to mushrooms is rich in substances that are excellent in anti-obesity, anti-allergy, liver function improvement effect, and the host pupa contains a large amount of immune enhancing substances.
길경(Platicodon grandiflorum A DC)은 도라지, 도랏, 길경채, 백약, 질경, 산도라지라고도 불리고 산과들에서 자라는 높이 40-100cm의 여러해살이풀로서, 번식은 종자로 잘된다. 봄가을에 뿌리를 채취하여 날것으로 먹거나 나물로 먹는다.Gilico (Platicodon grandiflorum A DC), also called bellflower, dorat, gilkyungchae, white medicine, plantain, and mountain bellflower, is a perennial herb that grows in mountains and has a height of 40-100 cm. In spring and autumn, roots are taken and eaten raw or as herbs.
생약의 길경(桔梗)은 뿌리의 껍질을 벗기거나 그대로 말린 것이며, 그 뿌리에는 약 2%의 사포닌, 프로사포닌으로서 3-O-β-글루코실플라티코디게닌, α-스피나스테롤, 쿠마린, 수지, 기름, 적은양의 알칼로이드, 많은 양의 이눌린, 플라티코디닌 등이 함유되어 있으며, 도라지 사포닌은 용혈작용이 있으며, 민간에서는 머리아픔, 성홍열, 콜레라, 위염, 적리 등에 이용하고 있다.The pathogen of the herbal medicine is peeled or dried as root, and about 2% of saponin at the root, 3-O-β-glucosylplaticodigenin, α-spinasterol, coumarin, Resin, oil, a small amount of alkaloids, a large amount of inulin, Platicodinin, etc., and the bellflower saponin has a hemolytic action, and in the civilian use is used for head pain, scarlet fever, cholera, gastritis, redness.
방풍(Saposhnikoviae divaricata Schiskin)은 산형화목 미나리과(Umbelliferae)에 속하는 세해살이 식물로서 진방풍, 산방풍, 병풍나물, 산방풍나무, 방풍나무뿌리 등으로 불리는 다년생 초본으로서 건조한 모래흙으로 된 풀밭에서 자생하고 있으며, 우리나라를 비롯하여 중국, 베트남, 몽골 등에 널리 분포하고 있다. 한방에 의한 방풍의 주요 효능으로는 발한, 해열, 진통, 이뇨, 중풍, 사지마비, 진해, 거담, 치통, 신경통, 류마티즘 등을 치료하며, 항균작용 및 바이러스 억제작용이 있는 것으로 알려져 있다.Windbreak (Saposhnikoviae divaricata Schiskin) is a perennial herb, belonging to the Umbelliferae family, which is a perennial herb that is called perennial wind, mountain wind, screen sprout, mountain wind tree, wind root, etc. It is widely distributed in Korea, China, Vietnam and Mongolia. The main effect of the windproof by oriental medicine is sweating, antipyretic, analgesic, diuretic, palsy, limb paralysis, Jinhae, expectorant, toothache, neuralgia, rheumatism, etc., and is known to have antibacterial and viral inhibitory effects.
편백(Chamaecyparis obtusa)은 측백나무과의 상록교목으로, 회목, 히노끼 및 노송나무라고도 한다. 높이는 30~40m이고 폭은 1~2m 가량이며, 나무껍질은 적갈색이고, 작은 바늘 모양의 잎이 가지에 밀생한다. 일본과 한국 남부에 분포하고, 성분에는 γ-카디넨(cadinene), α-테르피네올(terpineol) 및 보르네올(borneol) 등이 함유되어 있으며, 잎과 목재에는 1%의 정유가 함유되어 있다. 편백은 항원에 대한 항체를 생성시키는 작용을 하여 체내의 면연력을 향상시켜주고, 아토피, 천식 및 비염 등 알러지 질환을 일으키는 집먼지 진드기 퇴치를 위한 천연살충제로 많이 이용된다. 편백은 잎 또는 줄기, 가지를 추출한 것을 사용하는 것이 좋다. 상기 방풍과 편백 추출물은 단독으로 또는 혼합물 형태로 사용하여도 좋다.Chamaecyparis obtusa is an evergreen tree of the Cypressaceae family, also known as blackwood, hinoki and cypress. Its height is 30 ~ 40m, its width is about 1 ~ 2m, the bark is reddish brown, and small needle-shaped leaves grow in the branches. It is distributed in Japan and southern Korea, and contains γ-cardinene, α-terpineol and borneol, and leaves and wood contain 1% essential oil. . It is used as a natural insecticide to fight the house dust mite, which acts to produce antibodies to the antigen to improve the body's cotton softness, causing allergic diseases such as atopy, asthma and rhinitis. It is good to use extracts of leaves, stems and branches. The wind and cypress extracts may be used alone or in the form of a mixture.
이와 같은 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍, 편백을 포함하는 복합 식물 추출액은 그 자체로도 각 성분이 조화를 이루어 환자의 간과 위장을 보호하고 독성을 중화시키고 미세먼지에 의해 유발되는 기관지 염을 포함하는 호흡기 질환의 개선에 효율적으로 이용되는 등 다양한 이점을 제공할 수 있다.These complex plant extracts, including seaweed, shiitake mushroom or militaris Cordyceps sinensis, Giltyeong, windbreak, and cypress, are in harmony with each other to protect the liver and stomach of the patient, neutralize toxicity, and be caused by fine dust. It can provide various benefits such as being effectively used for the improvement of respiratory diseases including bronchitis.
본 발명의 미역귀를 포함하는 미세먼지 자극 호흡기 개선 질환의 개선용 식품의 제조 방법은 도 1에 나타낸 바와 같이 크게 미역귀 전처리 단계, 동결 단계, 해동 단계, 세척 단계, 선별 단계, 2차 세척 단계, 커팅 단계, 데침 단계, 냉각 단계, 발효 숙성 단계, 멸균 단계 및 포장 단계를 포함하여 이루어질 수 있고, 식물 혼합 추출액은 전처리 단계, 건조 단계, 혼합 단계, 추출 단계, 여과 단계, 반복 단계 및 농축 단계를 포함하여 이루어질 수 있다. 이하 개별 단계에 관련하여 상세히 설명한다.Method for producing a food for the improvement of fine dust stimulation respiratory disease, including the seaweed ear of the present invention is largely as shown in Figure 1 seaweed ear pretreatment step, freezing step, thawing step, washing step, screening step, secondary washing step, cutting It may comprise a step, a decimation step, a cooling step, a fermentation ripening step, a sterilization step and a packaging step, wherein the plant mixture extract comprises a pretreatment step, a drying step, a mixing step, an extraction step, a filtration step, a repeating step and a concentration step Can be done. The following describes the individual steps in detail.
a) 미역귀 전처리 단계a) seaweed pretreatment step
보통 식물 시료의 경우 세척에 의한 추출물 손실 및 주요성분 함량변화를 일으킬 수 있으므로 원료 세척 시 식물 조직의 손상을 최소화는 공정을 사용하는 것이 좋으며, 이러한 점을 고려하여 와류 세척기나 브러쉬 세척기를 사용하여 원료를 세척하고 이물질을 걸러주는 것이 좋다. 특히 미역귀는 흐르는 물에 여러 번 세척하여 표면에 부착된 이물질과 염분을 없애 줄 필요가 있다. 그러나, 긴급한 처리가 요구되는 상황에서 이 단계는 생략 가능하다.In general, plant samples can cause extract loss and major component content change due to washing, so it is recommended to use a process that minimizes damage to plant tissue when washing raw materials. It is a good idea to clean and filter out foreign objects. In particular, seaweed ears need to be washed several times in running water to remove foreign substances and salts from the surface. However, this step can be omitted in situations where urgent processing is required.
b) 동결 단계b) freezing step
전처리되거나 미처리된 미역귀를 냉동저장고에서 -30 ~ -40℃까지 동결시켜 키는 수일 내지 1년 동안 보관한다.Pre-treated or untreated seaweeds are stored in freezer for -30 ~ -40 ℃ to store for several days to 1 year.
c) 해동 단계c) thawing stage
동결된 미역귀를 냉동 저장고로 부터 꺼내어 10~20℃의 정제수나 지하수를 포함하는 세척수에 담궈서 해동시킨다. 이 과정에서는 유효 성분들은 미역귀 내에 존재하는 상태에서 얼음막에 부착된 각종 부유물과 미역귀 조직 내부에 포함된 염분 등이 탈염되어 미역귀의 염분이 제거된다.The frozen seaweed is removed from the freezer and thawed by soaking it in washing water containing 10-20 ℃ purified water or groundwater. In this process, the active ingredients are present in the seaweed ears, and various suspended matters attached to the ice film and the salts contained in the inside of the seaweed tissue are desalted to remove the salts of the seaweed ears.
d) 세척 단계d) washing step
상기 해동과 동시에 미역귀에 에어블로워 등을 이용하여 공기를 분사하여 미역귀를 세척하여 해동 과정에서 밖으로 우러나오는 염분과 이물질들의 탈리를 돕는다.Simultaneously with the thawing, the air is blown into the seaweed ear using an air blower to wash the seaweed ear to help desorption of salts and foreign substances coming out in the thawing process.
미역귀를 단순히 세척하는 것으로는 미역귀 표면만의 염분이 제거되어 수차례 세척하더라도 미역귀의 내부에 염분은 탈리되지 않아서 염분맛이 강하여 제품화에는 상당한 문제가 있다. 본 발명은 상기 해동 및 세척 단계에 의해 미역귀에 존재하는 알긴산 등을 포함하는 유효 성분은 용출되지 않는 상태에서 미역귀 내부의 염분만 필요한 정도로 제거되는 것에 기술적인 특징이 있다.Simply washing the seaweed ear removes the salt only on the surface of the seaweed, so even if washed several times, the salt does not desorb inside the seaweed, there is a significant salinity in the commercialization. The present invention is technically characterized in that the active ingredients including alginic acid and the like present in the seaweed ears are removed to the extent necessary for the salinity inside the seaweed ears by the thawing and washing steps.
e) 선별 단계e) screening step
세척 과정을 거친 미역귀로 부터 이물질과 염분 등이 포함된 세척수를 제거함과 동시에 이물질들을 선별하여 제거한다.From the seaweed, which has been washed, removes the water containing foreign substances and salt, and selects and removes the foreign substances.
f) 2차 세척 단계f) second washing step
선별 과정을 거친 미역귀에 세척수를 분사하여 미역귀를 재차 세척하여 깨끗한 상태로 한 다음 건조시킨다.Washing water is sprayed on the seaweed ear after the screening process, the seaweed ear is washed again, cleaned, and dried.
g) 커팅 단계g) cutting step
어느 정도 건조된 미역귀는 자동 커팅장치를 사용하여 소비자가 편리하게 이용할 수 있는 작은 크기로 얇게 채썰어서 세절한다. 그 크기는 제한할 필요는 없으나 소비자가 반찬이나 기호 식품으로써 이용하기에 적당한 정도이면 충분하고, 길이는 3~10cm 내외로 두께는 2~6mm로 슬라이스하여 절단하는 것이 바람직할 수 있다.The dried seaweed ears are sliced into thin slices and cut into small sizes that can be conveniently used by consumers using an automatic cutting device. It is not necessary to limit the size, but it is sufficient for the consumer to use it as a side dish or a favorite food, and it may be desirable to cut the slice into 3 to 10 cm in length and 2 to 6 mm in thickness.
h) 데침 단계h) needle stage
커팅된 미역귀 슬라이스를 데쳐서 조직을 부드럽게 하는 한편 조직감이 어느 정도 유지되게 하는 단계로서, 채 썬 미역귀를 뜨거운 물이나 끓는 물에 10~40초 동안 데치거나 또는 외부관에 85~95℃의 스팀이 공급되는 이중관의 내부관을 순차적으로 통과시켜서 2~5분 동안 데침 단계를 수행할 수 있다.A step of softening the tissue while maintaining the texture by scrubbing the sliced seaweed slices, while boiling the sliced seaweed in hot water or boiling water for 10 to 40 seconds, or supplying steam at 85-95 ° C to an external tube. By passing through the inner tube of the double tube to be sequentially can be carried out for 2 to 5 minutes.
i) 냉각 단계i) cooling stage
데친 미역귀 슬라이스를 자연 냉각시키거나 또는 상기 이중관에 연속적으로 연결되고 외부관에 냉각수가 공급되는 이중관의 내부관을 순차적으로 통과시켜서 2~5분 동안 냉각 단계를 수행할 수 있다.The cooling step may be performed for 2 to 5 minutes by naturally cooling the poached seaweed slice or by sequentially passing through the inner tube of the double tube continuously connected to the double tube and supplied with cooling water to the outer tube.
j) 발효 및 숙성 단계j) fermentation and ripening steps
이어서, 냉각 과정을 거친 미역귀를 복합 식물 추출액 중에 침지시켜 발효 및 숙성시키는데 발효 숙성 단계는 더 세분하여, j1) 침지 단계, j2) 미생물 접종 단계, j3 발효 단계, j4) 효소 첨가 단계 및 j5) 숙성 단계로 이루어지는 것이 바람직할 수 있다.Subsequently, the cooled seaweed ear is immersed in the complex plant extract for fermentation and maturation. The fermentation and aging step is further subdivided into j1) immersion step, j2) microbial inoculation step, j3 fermentation step, j4) enzyme addition step and j5) aging. It may be desirable to consist of steps.
j1) 침지 단계j1) immersion step
먼저, 데친 미역귀를 복합 식물 추출액 중에 침지시켜 미역귀가 충분히 잠기게 한다.First, boiled seaweed ears are immersed in the complex plant extract so that the seaweed ears are sufficiently submerged.
j2) 미생물 접종 단계, j2) microbial inoculation step,
이어서, 미역귀가 침지된 복합 식물 추출액에 발효용 균주를 0.1 ~ 3 중량%의 농도로 접종한다.Subsequently, the fermentation strain is inoculated at a concentration of 0.1 to 3% by weight in the complex plant extract immersed in seaweed.
상기 복합 식물 추출액은 미역귀, 표고버섯, 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 혼합 식물을 추출하여 제조된 것으로서 자세한 제조 방법에 대해서는 후술한다.The complex plant extract is prepared by extracting a mixed plant including seaweed, shiitake mushroom, militaris Cordyceps sinensis, Giltyeong, windbreak, and cypress, which will be described in detail later.
상기 단계에서 접종하기에 바람직한 발효용 균주는 미역귀 및 복합 식물 추출액의 기능성을 향상시키고 고분자 형태의 유용 성분들의 흡수가 용이하게 하는데 유익한 미생물이면 바람직하게 사용할 수 있다.Preferred fermentation strains for inoculation at this stage may be preferably used as long as the microorganisms are beneficial for improving the functionality of seaweed and complex plant extracts and facilitate the absorption of useful components in the form of polymers.
그러한 발효용 균주는 바람직하게는 바실러스(Bacillus) 속, 락토바실러스(Lactobacillus) 속, 사카로마이세스(Saccharamyces) 속 또는 셀룰로모나스(Cellulomonas) 속의 것을 이용할 수 있다.For such a fermentation strain may preferably be used to Bacillus (Bacillus) genus Lactobacillus bacteria (Lactobacillus), A saccharide in my process (Saccharamyces) genus Pseudomonas or the genus Cellulofine (Cellulomonas).
특히, 바실러스 섭틸리스(Bacillus subtilis), 바실러스 나토(Bacillus natto), 바실러스 아미로리퀴파시엔스(Bacillus amyloliquefaciens), 락토바실러스 아시도필루스(Lactobacillus acidophilus), 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 루테리(Lactobacillus reuteri), 사카로마이세스 세레비지애(Saccharomyces cerevisiae), 사카로마이세스 엘립소이더스(Saccharomyces ellipsoideus), 사카로마이세스 포르모센시스(Saccharomyces formosensis), 사카로마이세스 카를스베르겐시스(Saccharomyces carlsbergensis), 사카로마이세스 맨드슈리커스(Saccharomyces mandshuricus) 및 사카로마이세스 코레아누스(Saccharomyces coreanus), 셀룰로모나스 셀룰란스(Cellulomonas cellulans), 스트렙토코쿠스 테르모필루스(Streptococcus thermophilus) 및 류코노스톡 메센테로이데스(Leuconostoc mesenteroides), 광영양세균(Phototrophic bacteria), 효모(Yeast), EM균(유용미생물균)을 혼합하여 사용할 수도 있으며, 상업적으로 입수한 균주를 사용하여도 좋다.In particular, Bacillus subtilis , Bacillus natto , Bacillus amyloliquefaciens , Lactobacillus acidophilus , Lactobacillus plantarum , Lactobacillus plantarum Lactobacillus brevis (Lactobacillus brevis), Lactobacillus casei (Lactobacillus casei), Lactobacillus buffer momentum (Lactobacillus fermentum), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus ruteri (Lactobacillus reuteri), saccharose in my process three Levy jiae (Saccharomyces cerevisiae), saccharose in my process ellipsis Soy Ranges (Saccharomyces ellipsoideus), saccharose in my process formate Mohsen sheath (Saccharomyces formosensis), a saccharide My process car's Bergen sheath (Saccharomyces carlsbergensis), coarse My process mandrel Shurian a saccharide ( Saccharomyces mandshuricus ) and Saccharomyces corea nus ), Cellulomonas cellulans , Streptococcus thermophilus and Leuconostoc mesenteroides , Phototrophic bacteria , Yeast, EM bacteria (Useful microorganisms) may be used in combination, or commercially available strains may be used.
또한, 미생물 기탁 기관에 기탁된 것들을 입수하여 사용할 수 있으며, 그러한 것들의 예로는 바실러스 섭틸러스(Bacillus subtilis(KCTC 3239)), 락토바실러스 에시도필러스(Lactobacillus acidophilus(KCTC 3111)), 락토바실러스 플랜타륨(Lactobacillus plantarum(KCTC 3104)), 락토바실러스 에시도필루스 NCFM(Lactobacillus acidophilus NCFM, ATCC 기탁번호 SD5221), 락토바실러스 살리바리우스 Ls-33(Lactobacillus salivarius Ls-33, ATCC 기탁번호 SD5208) 및 락토바실러스 플랜타룸 Lp-115(Lactobacillus plantarum Lp-115, ATCC 기탁번호 SD5209), 사카로마이세스 세레비지아(Saccharomyces cerevisiae (KCTC 7915)) 균주를 들 수 있다.In addition, those deposited with microorganisms can be obtained and used, such as Bacillus subtilis (KCTC 3239), Lactobacillus acidophilus (KCTC 3111), Lactobacillus Lactobacillus plantarum (KCTC 3104), Lactobacillus acidophilus NCFM (ATCC Accession No. SD5221), Lactobacillus salivarius Ls-33 ( Lactobacillus salivarius Ls-33, ATCC Accession No. SD5208) and Lactobacillus Bacillus plantarum Lp-115 ( Lactobacillus plantarum Lp-115, ATCC Accession No. SD5209), Saccharomyces cerevisiae (KCTC 7915) strains.
j3) 발효 단계, j3) fermentation step,
이어서, 상기 접종물은 25 내지 43℃에서 3~10일 동안 발효시킨다. 발효는 필요에 따라서 교반하에 수행하거나 회전 발효기 상에서 수행하여도 좋다.The inoculum is then fermented at 25-43 ° C. for 3-10 days. Fermentation may be carried out with stirring or if necessary on a rotary fermenter.
j4) 효소 첨가 단계 j4) enzyme addition step
또한, 발효 단계는 라카아제(laccase), 셀룰라아제(cellulase), 펙티나아제(pectinase), 자일라나아제(xylanase), 폴리갈락투로나아제(polygalacturonase), 터마밀(termamyl), 아밀라아제(amylase) 및 글루코아밀라아제(glucoamylase)로 이루어진 군 중에서 선택되는 하나 이상의 효소 및 단당류, 이당류, 또는 다당류를 포함하는 당류의 존재하에서 수행하여 탄수화물 등의 유용 성분들을 저분자화하여 분해하는데 효율적일 수 있다. 상기 효소는 상업적으로 구입한 것을 사용해도 좋다.In addition, the fermentation step is laccase, cellulase, pectinase, xylanase, polygalacturonase, termamyl, amylase And one or more enzymes selected from the group consisting of glucoamylase and saccharides including monosaccharides, disaccharides, or polysaccharides, and thus may be efficient in reducing and degrading useful components such as carbohydrates. You may use the said commercially available enzyme.
상기 당류는 단당류, 이당류, 다당류를 포함할 수 있고, 이러한 예로서는 포도당, 과당, 맥아당, 전분 등이 포함된다. 또한, 설탕, 물엿 또는 꿀 등을 사용하여도 좋다. 상기 효소의 첨가량은 발효액을 기준으로 1~5 중량%로 사용하는 것이 좋다.The sugars may include monosaccharides, disaccharides, polysaccharides, and examples thereof include glucose, fructose, maltose, starch and the like. In addition, sugar, starch syrup or honey may be used. The addition amount of the enzyme is preferably used in 1 to 5% by weight based on the fermentation broth.
j5) 숙성 단계j5) ripening step
발효가 완료된 발효물은 통풍이 잘되는 그늘의 실온에서 3~10일 동안 숙성시키는 단계로서, 이러한 숙성과정을 거침으로써 충분히 발효 숙성이 일어나면서 유용한 기능성 성분들이 발효 원액 속에 녹아 들어가고 각종 효소, 조효소, 비타민, 유기산, 미네랄 등의 유효성분이 다량으로 함유되어 있을 뿐만 아니라, 기능성이 증대되고 향과 맛이 증대되고 소화 흡수가 잘 되는 상태가 되게 하는 것이 바람직할 수 있다.After fermentation is completed, fermented products are aged at room temperature in a well-ventilated shade for 3 to 10 days. Through this aging process, fermentation is sufficiently matured, and useful functional ingredients are dissolved in fermentation stock and various enzymes, coenzymes, and vitamins are used. In addition to containing a large amount of active ingredients, such as organic acids, minerals, it may be desirable to be in a state in which the functionality is increased, the flavor and taste are increased, and the digestion and absorption is good.
k) 포장 단계k) packing step
숙성이 완료된 미역귀 및 복합 식물 추출액을 규격대로 일정 단위의 제품으로 포장한다. 상기 단계에서 완성된 제품은 일정량을 포함하도록 소분하고 계량하여 충전 및 실링한다.After maturation, seaweed and complex plant extracts are packaged into products as standard units. The finished product in this step is subdivided, weighed, filled and sealed to contain a certain amount.
상기 충전 및 실링 공정은 자동 포장기계를 이용하거나 파우치 포장기, 밴드 실러 또는 로타리 타입의 자동 기계를 사용하여도 좋다. The filling and sealing process may use an automatic packaging machine or a pouch packing machine, a band sealer, or a rotary type automatic machine.
l) 멸균 단계l) sterilization step
상기 포장된 제품은 통상의 방식으로 멸균하여 제품의 보존성 및 유통기한을 확보할 수 있다. 예를 들면 상기 포장물은 필요에 따라 레토르트 멸균, 자외선 멸균 또는 습식 멸균을 수행하여 살균하여 보존성을 높인다.The packaged product can be sterilized in a conventional manner to ensure shelf life and shelf life of the product. For example, the package is sterilized by retort sterilization, ultraviolet sterilization, or wet sterilization as necessary to increase the shelf life.
이어서, 기준 및 규격에 준하여 성상, 이물질, 수분, 세균수, 대장균 등을 검사한 후 적합품에 한하여 출하한다.Subsequently, in accordance with the standards and specifications, the properties, foreign matters, moisture, bacteria count, E. coli, etc. are inspected and shipped only to suitable products.
이하, 상기 복합 식물 추출액의 제조에 관련하여 설명한다. 식물 혼합 추출액은 전처리 단계, 건조 단계, 혼합 단계, 추출 단계, 여과 단계, 반복 단계 및 농축 단계를 포함하여 이루어질 수 있다.Hereinafter, it demonstrates with respect to manufacture of the said complex plant extract. The plant mixture extract may comprise a pretreatment step, drying step, mixing step, extraction step, filtration step, repetition step and concentration step.
j1) 전처리 단계j1) pretreatment step
미역귀, 표고버섯, 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 식물을 개별적으로 전처리하는 단계로서, 상기 미역귀의 전처리에 준하여 실시하여 흙과 이물질 등을 제거하여 전처리한다.As a step of individually pretreating plants including seaweed ears, shiitake mushrooms, Militaris Cordyceps sinensis, Gilkyung, windproof and cypresses, the soil and foreign substances are removed by pretreatment according to the pretreatment of seaweed ears.
아울러, 원료를 구매하는 경우에는 식품공전, 식품첨가물공전 등에서 정한 기준, 규격에 적합한 것을 확인할 필요가 있다.In addition, when purchasing a raw material, it is necessary to confirm that it satisfies the standards and standards set forth in the Food Code, Food Additive Code, and the like.
j2) 건조 단계j2) drying step
세척 후 마찬가지로 식물 재료들을 바람이 잘 통하는 곳에서 적당히 자연 건조시키거나 저온 건조 또는 건조기를 사용하여 55~65℃의 온도에서 열풍 건조시키는 것이 바람직하다. 이때 건조 상태는 물기가 제거된 상태이면 충분하다.After washing, it is preferable to dry the plant materials in a well-ventilated place, either naturally or by hot air drying at a temperature of 55-65 ° C. using low temperature drying or a dryer. At this time, the dry state is sufficient if the water is removed.
j3) 혼합 단계j3) mixing step
건조된 식물 재료들은 미역귀 40~60 중량%, 표고버섯 또는 밀리타리스 동충하초 15~30%, 길경 15~30 중량%, 방풍 5~12중량% 및 편백 3~10중량%의 비율로 혼합하는 단계로서, 필요에 따라 이 단계를 생략하고 식물 재료들을 개별적으로 추출하여 사용하는 것도 기능성 증대의 측면에서 고려해볼 만하나 본 발명에서는 처리 시간 등의 물리적 여건 상 혼합 추출하는 것을 이용하였다.Dried plant materials are mixed at the rate of 40 ~ 60% by weight seaweed, 15-30% by shiitake mushroom or Militaris cordyceps, 15-30% by length, windproof 5-12% by weight and cypress 3-10% by weight As necessary, it is also possible to omit this step as necessary and to extract and use the plant materials individually, but in view of increasing the functionality, in the present invention, a mixed extraction was used in consideration of physical conditions such as processing time.
상기 미역귀의 사용량이 40중량% 미만인 경우에는 호흡기 질환의 개선 효과가 미약하고, 60 중량%를 초과할 경우에는 첨가량에 따른 상승 효과가 없어 경제성이 문제가 된다. 또한, 표고버섯이나 밀리타리스 동충하초는 15중량% 이하에서는 상승 작용 효과가 미약하고, 30중량%를 초과하는 경우에는 각 성분과의 조합에 의한 상승효과가 떨어져서 비경제적일 수 있다. 또한, 길경 추출물, 방풍뿌리 추출물 또는 편백 추출물은 정해진 중량% 이하에서는 호흡기 질환 개선 효과가 약하고, 초과하는 경우에는 전체적인 조성과 균형을 이루지 못하여 비경제적이므로, 상기 설정한 범위 내에서 전체적인 조성물의 안정적인 조화와 다양한 기능성을 최적으로 발휘할 수 있다.When the amount of seaweed ear is less than 40% by weight, the effect of improving respiratory disease is insignificant, and when it exceeds 60% by weight, there is no synergistic effect depending on the amount added. In addition, the shiitake mushroom or Militaris Cordyceps sinensis may have a weak synergistic effect at 15 wt% or less, and if it exceeds 30 wt%, the synergistic effect of the combination with each component may be inferior. In addition, the gilyeong extract, windproof root extract or cypress extract is less than a predetermined weight percent respiratory disease improvement effect, if exceeded, it is not economical because it is not balanced with the overall composition, stable harmony of the overall composition within the above set range And various functions can be exhibited optimally.
j4) 복합 식물 추출 단계j4) complex plant extraction step
일정 비로 혼합된 식물에 중량을 기준으로 5~25배수의 용매를 가하여 0.5~0.6 기압 및 60~80℃의 온도에서 7 내지 48시간 동안 1차 추출하여 추출물을 얻는다.5 to 25 times the number of solvents are added to the mixed plants in a certain ratio, and the extract is obtained by first extracting at a temperature of 0.5 to 0.6 atm and a temperature of 60 to 80 ° C. for 7 to 48 hours.
혼합 식물을 추출하기 위한 온도조건 표준화를 위한 온도조건 설정 실험결과 상기 혼합 식물의 추출은 0.5~0.6 기압, 60℃-70℃에서 7 내지 48시간 동안 추출하는 것이 가장 효과적인 것으로 나타났다. Experimental results of setting the temperature conditions for standardizing the temperature conditions for extracting the mixed plants showed that the extraction of the mixed plants was most effective for 7 to 48 hours at 0.5 to 0.6 atm, 60 ℃ -70 ℃.
한편, 추출 용매로는 물, 주정, 메탄올 및 에탄올로 이루어진 군 중에서 선택되는 하나 이상의 것을 사용할 수 있고, 용매의 양은 용매 사용량 표준화를 위한 실험결과 5~25배수로 추출했을 때 좋은 결과를 보여 에너지효율 및 경제성을 비교하였을 때 용매는 10배수로 첨가하여 추출하는 것이 가장 효과적일 수 있다. Meanwhile, as the extraction solvent, one or more selected from the group consisting of water, alcohol, methanol, and ethanol may be used, and the amount of the solvent shows good results when extracted with 5 to 25 times the results of experiments for standardizing solvent usage. In comparison with economics, the solvent may be most effective to extract by adding 10 times.
따라서, 대량생산을 위해서는 혼합 식물 추출 용매는 10배수, 추출온도는 65℃, 추출시간은 24시간이 가장 바람직할 수 있다.Therefore, for mass production, the mixed plant extraction solvent may be 10 times, the extraction temperature is 65 ℃, the extraction time may be the most desirable 24 hours.
j5) 여과 단계j5) filtration step
추출 단계 완료 후, 고형분을 여과막, 종이 여과지 또는 부직포를 사용하여 1차 여과하는 단계로서 부직포는 미세한 먼지, 점토, 이물질까지 깨끗이 여과하기 때문에 다른 천이나 물건을 사용하지 않고 부직포를 이용해 여과하는 것이 좋다.After the extraction step is completed, the solids are first filtered using a filtration membrane, paper filter paper, or nonwoven fabric. Since the nonwoven fabric is filtered to fine dust, clay, and foreign matter, it is preferable to filter with a nonwoven fabric without using other cloths or objects. .
j6) 및 j7) 반복 단계j6) and j7) repeat steps
이물질을 걸러내고 남은 고형분에 중량을 기준으로 5~25배수의 용매를 가하여 0.8~0.9 기압 및 80~95℃의 온도에서 3 내지 24시간 동안 2차 추출하여 추출물을 얻고 이를 여과하여 이물질을 걸러낸다. 이 단계에서 1차 추출 조건에 의해 미추출된 유용 성분을 더 추출하여 이용할 수 있다.Filter out foreign matter and add 5 ~ 25 times of solvent by weight to the remaining solids, extract for 2 to 3 hours at 0.8 ~ 0.9 atm and 80 ~ 95 ℃ to obtain extract and filter it to filter out foreign matter. . At this stage, useful components which are not extracted by the primary extraction conditions may be further extracted and used.
j8) 농축 단계j8) concentration step
상기 1, 2차 추출에 의해 얻어진 추출물을 합한 후 50~65℃의 온도에서 -0.08 ~ -0.09 MPa의 감압하에서 4 ~ 8 시간 동안 고형분의 brix°가 40 이상이 되게 농축한다. 감압 농축기를 사용하여 -0.08 ~ -0.09 MPa의 감압하에서 농축한 경우의 수율이 가장 양호하였고 색상은 암갈색의 액상었다. 이 단계에서는 회전식 진공 증발 장치를 이용하여도 좋다.After combining the extracts obtained by the first and second extraction, the brix ° of the solid content is concentrated to 40 or more for 4 to 8 hours under a reduced pressure of -0.08 to -0.09 MPa at a temperature of 50 to 65 ℃. The yield was the best when concentrated under reduced pressure of -0.08 ~ -0.09 MPa using a vacuum concentrator and the color was dark brown liquid. In this step, a rotary vacuum evaporator may be used.
본 발명에 의한 미세먼지 자극 호흡기 질환 개선용 식품은 후술하는 시험예에서 확인되는 바와 같이 MDA 생성량 억제율 시험에서 미세먼지에 의한 지질과산화 반응을 억제하였고, 또한, MTT assay를 통해서 미세먼지 처리하여 세포생존능을 확인한 바, 미역귀 복합 식물 추출물을 처리한 군에서 세포사멸에 대한 억제 효과에 대한 상승작용이 확인되었다. The food for improving the fine dust stimulation respiratory disease according to the present invention inhibited the lipid peroxidation reaction caused by the fine dust in the MDA production inhibition rate test, as confirmed in the test example described below, and further, by virtue of the fine dust treatment through the MTT assay, cell viability As a result, the synergistic effect on the inhibitory effect on apoptosis was confirmed in the group treated with Wakame complex plant extract.
따라서, 본 발명에 따른 미역귀를 포함하는 식품은 미세먼지에 의한 호흡기 질환을 예방하거나 개선을 위한 의약 또는 건강 기능 식품의 유효 성분으로 활용이 가능할 것으로 판단된다.Therefore, the food containing seaweed ears according to the present invention is considered to be possible to use as an active ingredient of a medicinal or health functional food for preventing or improving respiratory diseases caused by fine dust.
본 발명에 있어서 미세먼지 유발 호흡기 질환은 호흡기 염증성 폐질환, 만성 폐쇄성 폐질환, 부비강염, 알레르기성 비염, 하기도 감염증, 급만성기관지염, 폐기종, 폐렴, 천식, 기관지염, 기관지 확장증, 인후염, 편도염, 및 후두염으로 이루어진 군으로부터 선택되는 하나 이상의 질환을 포함할 수 있다.In the present invention, the fine dust-induced respiratory diseases include respiratory inflammatory lung disease, chronic obstructive pulmonary disease, sinusitis, allergic rhinitis, lower respiratory tract infection, acute bronchitis, emphysema, pneumonia, asthma, bronchitis, bronchodilation, pharyngitis, tonsillitis, and laryngitis It may include one or more diseases selected from the group consisting of.
본 발명의 의약은 다양한 경로로 투여될 수 있다. 다양한 투여 방식이 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 또는 피하 주사에 의해 투여될 수 있다.The medicine of the present invention can be administered by various routes. Various modes of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, or subcutaneous injection.
또한, 상기 의약 조성물은 실제 임상투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 제제화할 경우에는 보통 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용할 수 있다.In addition, the pharmaceutical composition may be administered in a variety of oral and parenteral formulations during actual clinical administration, and when formulated, diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used. Can be used.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include, for example, starch, calcium carbonate, sucrose or lactose, It is prepared by mixing gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
본 발명의 미역귀 함유 식품 조성물의 투여 용량은 환자의 체충, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 달라질 수 있으며, 의사 또는 약사의 판단에 따라 일정 시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다. 예컨대, 유효성분 함량 기준으로 1일 투여량이 0.001 내지 500㎎/㎏, 바람직하게는 0.1 내지 200㎎/㎏일 수 있다.Dose of the seaweed-containing food composition of the present invention may vary depending on the patient's worm, age, sex, health status, diet, administration time, administration method, excretion rate and the severity of the disease, depending on the judgment of the doctor or pharmacist It may be administered once or several times a day at intervals of time. For example, the daily dose may be 0.001 to 500 mg / kg, preferably 0.1 to 200 mg / kg, based on the active ingredient content.
또한, 본 발명에 따른 기능성 식품 조성물은 당해 분야에서의 통상적인 방법에 따라, 예를 들면 분말, 과립, 환, 정제, 캡슐, 파우치, 액상 또는 음료 형태를 포함하는 제형으로 제공할 수 있다.In addition, the functional food composition according to the present invention may be provided in a formulation including, for example, powder, granules, pills, tablets, capsules, pouches, liquid or beverage forms according to conventional methods in the art.
본 발명의 식품의 섭취량은 그 제제 형태, 투여 방법, 사용 목적 및 이것에 적용되는 개체의 연령, 체중, 증상에 따라서 적절히 설정되고, 일정하지 않지만 일반적으로는 제제 중에 함유되는 유효성분의 양은 성인 1일당, 예컨대 0.001 mg/㎏∼500 ㎎/㎏이다. 물론 복용량은, 각종 조건에 의해서 변동하기 때문에, 상기 섭취량보다 적은 양으로 충분한 경우도 있고, 또는 범위를 초과하여 필요한 경우도 있다.The intake amount of the food of the present invention is appropriately set according to the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the individual to which it is applied, and the amount of the active ingredient contained in the preparation is generally not constant. Per day, such as from 0.001 mg / kg to 500 mg / kg. Of course, since the dose varies depending on various conditions, an amount smaller than the intake amount may be sufficient, or it may be necessary beyond the range.
또한, 본 발명의 조성물이 기능성 식품(건강기능식품 및 일반 식품) 조성물로 제조되는 경우에는 식품에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 감미료, 예를 들면 감초, 비타민 C, 구연산, 니코틴산, 안식향산나트륨, 아스파탐, 사카린, 펙틴, 말리톨, 솔비톨, 자일리톨, 구아검, 탈지분유 및 올리고당으로 이루어진 군 중에서 선택되는 하나 이상의 성분을 추가하여 기호도나 미감을 증대시킬 수 있다.In addition, when the composition of the present invention is prepared as a functional food (health functional food and general food) composition may include ingredients that are commonly added to food, for example, proteins, carbohydrates, fats, sweeteners, such as For example, licorice, vitamin C, citric acid, nicotinic acid, sodium benzoate, aspartame, saccharin, pectin, malitol, sorbitol, xylitol, guar gum, skim milk powder and oligosaccharides can be added to enhance palatability or taste. You can.
이들은 본 발명의 조성물의 전체 중량을 기준으로 약 0.01~20 중량%로 사용하는 것이 적절하다.They are suitably used at about 0.01 to 20% by weight based on the total weight of the composition of the present invention.
음료수는, 예를 들면, 상기 미역귀 함유 발효 숙성물을 0.01~20 중량%으로 넣고, 감초 0.01~2 중량%, 구연산을 0.01~2 중량%, 사과산 0.01~2 중량%, 타우린 0.1∼2 중량%, 비타민 C 0.01~2 중량%, 비타민 B1 0.01~2 중량%, 바이오틴 0.01~2 중량%, 액상과당 0.01~20 중량% 폴리덱스트로스 0.1~3 중량%, 배농축액 0.1~1 중량%, 벌꿀 0.1~0.5중량%, 젖산칼슘 0.01~1 중량%, 향료 0.1~1 중량%, 색소 0.01~0.05 중량%, 구연산나트륨 0.01~0.5중량%, 스테비텐후레쉬 0.01~0.5 중량%, 니코틴산아미드 0.01~0.5 중량%, 로얄제리추출물 0.01~0.5 중량%, L-멘톨 0.0001~0.5 중량%등을 단독 또는 혼합하여 첨가하여 기능성 음료수로 제조할 수 있다.Drinking water is, for example, put the seaweed ear containing fermented matured at 0.01 to 20% by weight, licorice 0.01-2% by weight, citric acid 0.01-2% by weight, malic acid 0.01-2% by weight, taurine 0.1-2% by weight , 0.01 to 2% by weight of vitamin C, 0.01 to 2% by weight of vitamin B1, 0.01 to 2% by weight of biotin, 0.01 to 20% by weight of liquid fructose, 0.1 to 3% by weight of polydextrose, 0.1 to 1% by weight of pear concentrate, 0.1 to 0.5 of honey Weight%, calcium lactate 0.01 to 1% by weight, fragrance 0.1 to 1% by weight, pigment 0.01 to 0.05% by weight, sodium citrate 0.01 to 0.5% by weight, stebitene fresh 0.01 to 0.5% by weight, nicotinic acid amide 0.01 to 0.5% by weight, Royal jelly extract 0.01 ~ 0.5% by weight, L- menthol 0.0001 ~ 0.5% by weight or the like can be added to prepare a functional beverage.
<실시예><Example>
이하, 본 발명은 다음의 대표적인 실시예에 의하여 더욱 구체적으로 설명되나, 본 발명이 이들 실시예에 의해 어떤 식으로든 제한되는 것은 아니다. 각 값은 3회 반복 시험한 것을 평균 ± 표준 편차로 나타내었다.Hereinafter, the present invention is described in more detail by the following representative examples, but the present invention is not limited in any way by these examples. Each value is the mean ± standard deviation of three replicates.
실시예Example 1: 복합 식물 추출물의 제조 1: Preparation of Complex Plant Extracts
미역귀, 표고버섯, 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 식물을 개별적으로 세척하여 이물질 등을 제거한 후 통풍이 잘되는 곳에 12시간 동안 방치하여 자연 건조시키고 다음의 표 1에 나타낸 배합비로 혼합한 복합 식물 100Kg을 1 Ton 추출기에 넣고 5배수의 주정을 가하여 0.5 기압 및 65℃의 온도에서 10시간 동안 추출하여 1차 추출물을 얻었다. 이를 부직포로 여과한 후 남은 고형물에 정제수 600리터를 가한 후 0.8 기압 및 85℃의 온도에서 5시간 동안 2차로 추출하여 고형분을 여과시킨 후 상기 1, 2차 추출에 의해 얻은 추출물을 1:1의 중량비로 합하고, 55℃의 온도에서 -0.08 MPa의 감압하에서 4시간 동안 농축하였다. 고형분의 brix는 53~56으로 측정되었다. Plants including seaweed, shiitake mushrooms, militaris cordyceps, gilyeong, windproof and cypress are individually washed to remove foreign substances, and left in a well-ventilated place for 12 hours to dry naturally and mixed in the mixing ratio shown in Table 1 below. 100 Kg of a composite plant was put in a 1 Ton extractor, and 5 times of alcohol was added thereto, followed by extraction at 0.5 atmosphere and a temperature of 65 ° C. for 10 hours to obtain a primary extract. After filtering it with a nonwoven fabric, 600 liters of purified water was added to the remaining solid, and then extracted for 2 hours at 0.8 atm and 85 ° C. for 2 hours to filter the solids. The extract obtained by the first and second extraction was 1: 1. Combined by weight ratio and concentrated for 4 hours under reduced pressure of -0.08 MPa at a temperature of 55 ° C. Solid brix was measured between 53 and 56.
실시예Example 6: 미역귀를 포함하는 식품의 제조 6: Preparation of food containing seaweed ears
채취된 미역귀 100Kg을 흐르는 물에 세척한 다음 이를 -35℃로 동결시킨 다음 3개월 동안 그 상태로 보관한 다음 이를 13~15℃의 세척수에 침지시킨 상태에서 에어블로워를 분사하여 이물질을 탈리시킨 다음 세척수를 버리고 다시 새로운 새척수를 분사하여 세척한 다음 어느 정도 건조시켜서 3cm의 길이로 커팅하고 이를 외관에 스팀이 흐르는 이중관의 내부를 통과시켜 데친 후 마찬가지의 이중관을 통과시켜 냉각시켰다. 그 다음, 실시예 3에서 제조된 복합 식물 추출액 250Kg에 침지시킨 후 발효 균주를 1Kg을 접종한 후 30℃에서 3일 동안 발효시켰다. 발효 단계에서는 셀룰라아제와 설탕을 각각 5Kg을 첨가하여 수행하였다. 발효가 완료된 발효물은 통풍이 잘되는 그늘의 실온에서 3일 동안 숙성시키고, 이를 소단위로 밀봉 포장한 후 레토르트 멸균하여 제품을 제조하였다. 이후의 시험예에서는 숙성된 발효물을 분쇄한 것을 사용하였다.After washing 100Kg of the collected seaweeds in running water, freeze it at -35 ℃ and store it for 3 months, then desorb it by spraying an air blower while it is immersed in 13 ~ 15 ℃ washing water. After discarding the washing water and sprayed again with fresh new spinal cord, and then dried to some extent cut to a length of 3cm, it was passed through the inside of the double pipe flowing steam to the outside and then cooled through the same double pipe. Then, after immersing in 250Kg of the composite plant extract prepared in Example 3, the fermentation strain was inoculated with 1Kg and then fermented at 30 ° C for 3 days. In the fermentation step, 5 Kg of cellulase and sugar were added. Fermentation is completed fermentation was aged for 3 days at room temperature in a well-ventilated shade, sealed packaging in small units and then retort sterilized to prepare a product. In the following test example, the aged fermented product was ground.
시험예Test Example
다음의 시험예에서는 호흡기 조직 내 in vitro 효능과 기관지 상피세포 및 대식세포의 염증 반응 억제에 관한 시험을 수행하였다.In the following test examples, in vitro efficacy in respiratory tissues and tests for suppressing the inflammatory response of bronchial epithelial cells and macrophages were performed.
모든 실험에서 실시예 6의 제품과 비교예의 것을 대상으로 효능을 평가하였다. 미세먼지는 세포생존에 크게 영향을 미치지 않는 50㎍/mL 농도로 첨가하였다. 각 값은 3회 측정한 값을 평균±SD로 나타내었다.In all experiments, the efficacy of the product of Example 6 and that of the comparative example was evaluated. Fine dust was added at a concentration of 50 µg / mL which does not significantly affect cell survival. Each value represents the mean ± SD of three measurements.
시험예Test Example 1: 실험동물 폐 조직 준비 1: Preparation of experimental animal lung tissue
실험동물(ICR mouse, male, 8 week)을 해부 전 24시간 절식시킨 후 ether 마취 하에서 개복한 후 폐 조직을 분리하여 분석할 때까지 -70℃에 보관하였다. 폐 조직은 멸균생리식염수로 수 회 씻어낸 후 lysis buffer를 첨가하여 lysis 및 파쇄하여 원심분리(10,000 x g) 후 폐 조직 균질액을 조제하였다. BCA kit로 단백질을 정량하고 시료는 적정 농도(100 ㎍ - 1,000 ㎍)를 산정하여 폐 조직 균질액에 시료를 1시간 처리 또는 미세먼지+시료를 처리 후 후속 in vitro 시험을 수행하였다.Experimental animals (ICR mouse, male, 8 weeks) were fasted for 24 hours before dissection, and then opened under ether anesthesia, and lung tissue was separated and stored at -70 ° C until analysis. Lung tissue was washed several times with sterile physiological saline, lysis buffer was added, lysis and crushing were centrifuged (10,000 x g), and lung tissue homogenates were prepared. Proteins were quantified by BCA kit, and the samples were titrated (100 ㎍-1,000 ㎍), and the samples were treated with lung tissue homogenate for 1 hour or fine dust + sample, followed by in vitro testing.
시험예Test Example 2: 폐 조직 내 미역귀 함유 식품 소재의 지질 과산화 분석 2: Lipid Peroxidation Analysis of Food Ingredients Containing Seaweed in Lung Tissue
미세먼지 자극 후 실시예 6에 따른 미역귀 함유 식품의 항산화능 변화를 분석하기 위해 폐조직 내 지질 과산화 억제능을 평가하였다. 지질 과산화의 분석은 MDA 생성량을 통해 이루어지며 시료 및 대조군의 조직 균질액에서 MDA 생성량을 측정하여 비교분석하였다. In order to analyze the antioxidant activity of the seaweed ear containing food according to Example 6 after the fine dust stimulation was evaluated the lipid peroxidation inhibitory ability in the lung tissue. Lipid peroxidation was analyzed through MDA production, and MDA production in tissue homogenates of samples and controls was measured and compared.
일반대조군으로 시료 대신 vehicle을 사용하였고 음성대조군은 폐조직 균질액에 미세먼지 자극(50㎍/mL)만 준 것과 FeSO4만 자극시킨 것을 사용하였으며, 양성대조군으로는 수용성 vitamin C인 ascorbic acid(10㎍) + 미세먼지 자극(50㎍/mL), polyphenol인 gallic acid(10㎍) + 미세먼지 자극(50㎍/mL), 및 flavonoid인 naringin(10㎍) + 미세먼지 자극(50㎍/mL)으로 수행하였다. 실험군은 실시예 6의 미역귀 함유 식품(분말 함유 액상)로 5 ㎍, 10 ㎍, 20 ㎍ + 미세먼지 자극(50㎍/mL)의 농도로 수행하였다. 도 2는 미역귀 함유 식품의 미세먼지 유발 지질 과산화 억제 결과를 나타내는 그라프도이다. The vehicle was used instead of the sample as a general control group, and the negative control group was used to give only fine dust stimulation (50㎍ / mL) to the lung tissue homogenate and to stimulate only FeSO 4 , and the positive control group was ascorbic acid (10). ㎍) + fine dust stimulation (50 μg / mL), gallic acid (10 μg) as polyphenol + fine dust stimulation (50 μg / mL), and naringin (10 μg) as flavonoid + fine dust stimulation (50 μg / mL) Was performed. The experimental group was carried out at the concentration of 5 μg, 10 μg, 20 μg + fine dust stimulation (50 μg / mL) in the seaweed-containing food (powder-containing liquid) of Example 6. Figure 2 is a graph showing the results of inhibiting fine dust-induced lipid peroxidation of seaweeds containing foods.
그 결과, 시료를 녹인 buffer를 처리한 일반대조군의 MDA 생성량은 3.6273±0.1076 nmol MDA/g, 미세먼지만 자극시킨 음성대조군의 MDA 생성량은 4.5625±±0.1267 nmol MDA/g, FeSO4만 자극시킨 음성대조군의 MDA 생성량은 5.1724±0.1356 nmol MDA/g, 양성대조군 ascorbic acid + 미세먼지에서는 4.0632±0.2172 nmol MDA/g, gallic acid + 미세먼지에서는 4.4205±0.1363 nmol MDA/g, 양성대조군 naringin + 미세먼지에서는 4.4302±0.2727 nmol MDA/g, 실험군인 미역귀 함유 식품 5㎍ + 미세먼지에서 4.3266±0.2691 nmol MDA/g, 10㎍ + 미세 먼지에서 3.9653±0.2126 nmol MDA/g, 20㎍ + 미세먼지에서 3.6327±0.2479 nmol MDA/g의 생성량을 보였다.As a result, the amount of MDA produced by the normal control treated with the buffer in which the sample was dissolved was 3.6273 ± 0.1076 nmol MDA / g, and the amount of MDA produced by the microcontrolled negative control was 4.5625 ±± 0.1267 nmol MDA / g and negatively stimulated with FeSO 4 . MDA production in the control group was 5.1724 ± 0.1356 nmol MDA / g, in the positive control ascorbic acid + fine dust 4.0632 ± 0.2172 nmol MDA / g, in the gallic acid + fine dust 4.4205 ± 0.1363 nmol MDA / g, and in the positive control naringin + fine dust 4.4302 ± 0.2727 nmol MDA / g, food containing seaweed ear, experimental group 4.3266 ± 0.2691 nmol MDA / g, 10μg + 3.9653 ± 0.2126 nmol MDA / g, 20μg + fine dust The production amount of nmol MDA / g was shown.
이러한 결과는 폐 조직에서는 미세먼지 자극 시 생성되는 MDA량은 FeSO4 자극시 생성되는 MDA량 보다 낮았으며, 양성대조군과 실험군의 시료의 MDA 생성량을 비교분석하면 미역귀 함유 식품이 고농도에서 자극전의 수준까지 MDA 생성을 억제하였음을 나타낸다.These results indicate that the amount of MDA produced during stimulation of fine dust in lung tissue was lower than the amount of MDA produced during FeSO 4 stimulation. Indicates that MDA production was inhibited.
실험예Experimental Example 3: 기관지 염증 억제 시험 3: bronchial inflammation inhibition test
실시예 6에서 제조된 식품이 천식 및 만성폐쇄성폐질환 모델에서 폐기관지 염증 억제 효과가 있는지를 확인하기 위해, 감작된 마우스에 항원을 노출시켜 유발되는 폐기관지의 백혈구 증가반응을 확인(Pharmacological Research, 2010, 61, 288~297; Biochemical Pharmacology, 2010, 79, 888~896)하였다. In order to confirm whether the food prepared in Example 6 has an inhibitory effect on bronchoinflammatory inflammation in the asthma and chronic obstructive pulmonary disease model, the leukocyte increase response of bronchiole caused by exposing the antigen to sensitized mice was confirmed (Pharmacological Research, 2010, 61, 288-297; Biochemical Pharmacology, 2010, 79, 888-896).
이를 위해, 실험 동물에 10㎍의 난알부민(Ovalbumin, [0074] OVA, sigma)과 수산화알루미늄(4mg, aluminium hydroxide, Alum, Pierce) 1:1 혼합액 02㎖을 0, 7 및 14일에 복강 내 투여하여 감작시켰다. 최종 감작일로부터 8일 후와 10일 후에 10% 난알부민을 고압의 압축공기를 이용하여 에어로졸로 만들어 50분간 분무하여 기도염증을 유발하였다. 각 시험물질(00㎎/㎏, bid)의 투여는 첫 감작 후 21일부터 23일까지 오전 오후 하루 두 차례에 걸쳐 경구 투여하여 Challenge 하였다. 마지막 Challenge 24시간 후에 인산완충용액(pH 7.2) 15㎖을 이용하여 기관지폐포 세척을 하여 기관지폐포 세척액을 모았다. 세척액 중의 백혈구 세포수는 헤마톨로지 분석기(Hematology analyzer, Drew Scientific Inc, HEMAVET HV950FS, M-950HV)를 사용하여 백혈구수를 계수하였다. 이에 대한 결과는 음성대조군(1% CMC[carboxymethyl cellulose] 투여군)의 백혈구 세포수 정도를 기준으로 폐기관지 염증 억제율(%)을 계산하여 하기 표 2에 나타냈다.To this end, 10 μl of egg albumin (Ovalbumin, OVA, sigma) and aluminum hydroxide (4 mg, aluminum hydroxide, Alum, Pierce) 1: 1 mixed solution in experimental animals intraperitoneally on
상기 표 2에서 보는 바와 같이, 본 발명의 실시예에 따른 식품은 기관지폐포 세척액의 백혈구 수를 억제하는 효과가 우수함을 알 수 있었으며, 이로 인해 상기 추출물들이 염증 억제 발생이 뛰어남을 확인할 수 있었다.As shown in Table 2, the food according to the embodiment of the present invention was found to have an excellent effect of inhibiting the white blood cell count of the bronchoalveolar lavage fluid, it was confirmed that the extract is excellent in the inhibition of inflammation.
시험예Test Example 4: 미역귀 제품의 미세먼지에 의한 세포 생존율 측정- 4: Determination of Cell Viability by Fine Dust of Seaweeds MTTMTT assay assay
미세먼지의 독성에 의한 미역귀 함유 제품의 세포 생존율 감소 억제 효과를 알아보기 위해 Raw264.7 세포주(한국세포주은행, 40071)를 이용하여 MTT assay를 수행하였다. MTT assay was performed using Raw264.7 cell line (Korea Cell Line Bank, 40071) in order to investigate the inhibitory effect of the reduction of cell viability of seaweed ear containing products by the toxicity of fine dust.
Raw264.7 세포는 fetal bovine serum(FBS)이 10% 포함된 RPMI-1640 media에서 24시간 배양 후 세포가 90-100%로 배양되었을 때 PM10(NIST, 1648a, 50μg/ml)을 첨가하고, 대조군은 세포배양만 시행하고 PM10 처리를 하지 않은 것으로 수행하였다.Raw264.7 cells were added with PM10 (NIST, 1648a, 50μg / ml) when cells were cultured at 90-100% after 24 hours in RPMI-1640 media containing 10% fetal bovine serum (FBS). Was performed only in cell culture and not treated with PM10.
세포를 96-well plates에 분주한 뒤 12시간 동안 배양한 후, 각 시료를 세포에 처리하여 24시간 동안 배양하고, 이후 MTT 용액(최종농도: 0.5 mg/mL)을 가하고 37℃에서 4시간 더 배양하여 MTT를 환원시켜 생성된 formazan이 배지에 떨어져 나가지 않도록 배지를 제거하고 DMSO를 100㎕ 분주하여 10분 동안 혼합한 후 540nm에서 흡광도를 측정하였다.After dispensing cells into 96-well plates and incubating for 12 hours, each sample was treated with cells and incubated for 24 hours, after which MTT solution (final concentration: 0.5 mg / mL) was added and further 4 hours at 37 ° C. The culture was removed to prevent formazan from culturing by reducing MTT, and 100 μl of DMSO was mixed for 10 minutes, and then absorbance was measured at 540 nm.
그 결과를 도 3에 나타내었다. 도 3은 미역귀 제품의 Raw264.7 세포주에 대한 PM-유발 세포 치사의 보호에 미치는 영향을 나타낸 그라프도이다.The results are shown in FIG. Figure 3 is a graph showing the effect on protection of PM-induced cell death against Raw264.7 cell line of seaweed products.
그 결과, 미세먼지만 처리한 군에서는 생존율이 약 43%로 감소한 반면, 미역귀함유 시료는 10, 20, 30, 50, 100μg/ml 농도로 처리한 군에서 각각 55, 66, 76, 82, 89%의 세포 생존율을 나타내었고, 농도가 증가할수록 세포생존율이 증가하였다. 이와 같은 결과로부터 미역귀 함유 제품의 미세먼지 유발 세포 보호 효과를 확인할 수 있었다.As a result, the survival rate was reduced to about 43% in the microdust-treated group, while the samples containing seaweeds were 55, 66, 76, 82, and 89 in the 10, 20, 30, 50, and 100 μg / ml concentrations, respectively. Cell viability was shown as%, cell viability increased with increasing concentration. From these results, it was confirmed that the microdust-induced cell protective effect of seaweeds containing products.
시험예Test Example 5: 관능 평가 5: sensory evaluation
상기 실시예 6에 따른 제조된 미역귀 제품에 대한 관능검사는 관능적 식별 능력이 있는 관능검사요원 30명을 선정하여 품질의 평가 척도는 7점 척도법(7점: 아주 좋다, 6점: 좋다. 5점: 조금 좋다, 4점: 보통이다, 3점: 조금 나쁘다, 2점: 나쁘다, 1점: 아주 나쁘다)으로 하였다.As for the sensory test on the seaweed return product prepared according to Example 6, 30 sensory test personnel with sensory discrimination ability were selected, and the evaluation scale of the quality was 7-point scale (7 points: very good, 6 points: good. : A little good, 4 points: normal, 3 points: a little bad, 2 points: bad, 1 point: very bad).
관능검사 항목으로는 식감, 감칠맛, 향 및 전체적인 기호도와 같은 총 5가지 관능항목으로 평가하였으며, 결과는 ANOVA를 이용하여 5% 수준에서 Duncan's multiple range test에 의해 각 시료간의 유의적인 차이를 검증하였다. 그 결과를 채점한 후, 이를 평균하여 표 3(평균값±표준편차)에 나타내었다.The sensory test items were evaluated by five sensory items such as texture, texture, flavor, and overall acceptability. The results were verified by Duncan's multiple range test at 5% level using ANOVA. After scoring the result, it was averaged and shown in Table 3 (mean value + standard deviation).
그 결과 실시예 6의 제품은 식감과 감칠맛, 향 및 전체적인 기호도에서 매우 우수하였고, 전반적으로 모든 항목에서 비교예의 것에 비하여 현저히 우수한 결과를 나타내었다. 상기 표 3의 결과로 볼 때, 본 발명의 실시예의 제품들은 연령대에 상관 없이 비교품에 비하여 종합적으로 우수한 것을 확인할 수 있었다. As a result, the product of Example 6 was very excellent in texture and texture, aroma and overall acceptability, and showed a significantly better result than the comparative example in all items. As a result of Table 3, it was confirmed that the products of the embodiments of the present invention are comprehensively superior to the comparative product regardless of age group.
이상의 실시예 및 시험예에서 확인되는 바와 같이, 본 발명에 따른 미역귀 함유 식품은 추출물은 미세먼지에 의한 호흡기 질환을 예방하거나 개선을 위한 건강 기능 제품으로 활용이 가능할 것으로 판단된다.As confirmed in the above examples and test examples, the seaweed ear containing food according to the present invention is determined that the extract can be used as a health functional product for preventing or improving respiratory diseases caused by fine dust.
이상, 첨부된 도면을 참조하여 본 발명의 바람직한 일 실시예를 설명하였지만, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 본 발명의 그 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 일 실시예는 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.As mentioned above, although an exemplary embodiment of the present invention has been described with reference to the accompanying drawings, those skilled in the art to which the present invention pertains may change to other specific forms without changing the technical spirit or essential features of the present invention. It will be appreciated that it may be practiced. Therefore, it should be understood that one embodiment described above is illustrative in all respects and not restrictive.
Claims (4)
b) 전처리된 미역귀를 -30 ~ -40℃까지 동결시키는 단계;
c) 동결된 미역귀를 세척수에 담궈서 해동시키는 단계;
d) 상기 해동과 동시에 미역귀에 공기를 분사하여 세척하는 단계;
e) 상기 세척수 및 이에 포함된 이물질을 제거하여 미역귀를 선별하는 단계;
f) 미역귀에 세척수를 공급하여 2차 세척하는 단계;
g) 세척된 미역귀를 일정 크기로 커팅하는 단계;
h) 커팅된 미역귀를 데치는 단계;
i) 데친 미역귀 슬라이스를 냉각시키는 단계;
j) 냉각된 미역귀 슬라이스를 복합 식물 추출액 중에 침지시켜 발효 및 숙성시키는 단계;
k) 숙성이 완료된 미역귀 및 복합 식물 추출액을 일정 단위의 제품으로 포장하는 단계; 및
l) 포장된 제품을 멸균하는 단계;를 포함하고,
상기 복합 식물 추출액은 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 혼합 식물을 추출하여 제조된 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법.a) pretreatment of the collected seaweed;
b) freezing the pretreated seaweed to −30 to −40 ° C .;
c) thawing by immersing the frozen seaweed in wash water;
d) spraying and washing air into seaweed at the same time as the thawing;
e) screening seaweed ears by removing the washing water and foreign matter contained therein;
f) supplying the wash water to seaweed ears to perform the second washing;
g) cutting the washed seaweed into a certain size;
h) blanching the cut seaweed;
i) cooling the poached seaweed slice;
j) fermenting and aging by immersing the cooled seaweed slice in a complex plant extract;
k) packaging the seaweed and complex plant extracts which have been matured into a unit of product; And
l) sterilizing the packaged product;
The complex plant extract is prepared by extracting a mixed plant comprising seaweed, shiitake mushroom or militaris Cordyceps sinensis, Giltyeong, windbreak and cypresses.
상기 복합 식물 추출액은
j1) 미역귀, 표고버섯 또는 밀리타리스 동충하초, 길경, 방풍 및 편백을 포함하는 식물을 개별적으로 전처리하는 단계;
j2) 전처리된 식물을 건조시키는 단계;
j3) 미역귀 40~60 중량%, 표고버섯 또는 밀리타리스 동충하초 15~30%, 길경 15~30 중량%, 방풍 5~12중량% 및 편백 3~10중량%의 비율로 혼합하는 단계;
j4) 혼합된 식물에 중량을 기준으로 5~25배수의 용매를 가하여 0.5~0.6 기압 및 60~80℃의 온도에서 7 내지 48시간 동안 1차 추출하여 추출물을 얻는 공정;
j5) 얻어진 추출물을 여과하여 이물질을 걸러내는 단계;
j6) 이물질을 걸러내고 남은 고형분에 중량을 기준으로 5~25배수의 용매를 가하여 0.8~0.9 기압 및 80~95℃의 온도에서 3 내지 24시간 동안 2차 추출하여 추출물을 얻는 단계;
j7) 얻어진 추출물을 여과하여 이물질을 걸러내는 단계;
j8) 상기 1, 2차 추출에 의해 얻어진 추출물을 합한 후 50~65℃의 온도에서 -0.08 ~ -0.09 MPA의 감압하에서 4~8시간 동안 고형분의 brix°가 40 이상이 되게 농축하는 단계;에 의해 제조되는 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법.The method according to claim 1,
The complex plant extract is
j1) individually pretreatment of plants including seaweed, shiitake mushrooms or militaris cordyceps, gilyeong, windproof and cypress;
j2) drying the pretreated plant;
j3) mixing at a rate of 40 ~ 60% by weight seaweed, 15-30% of shiitake mushrooms or Militaris Cordyceps sinensis, 15-30% by weight, windproof 5-12% by weight and cypress 3-10% by weight;
j4) adding a solvent of 5 to 25 times the weight of the mixed plant by weight to obtain a extract by primary extraction for 7 to 48 hours at 0.5 to 0.6 atm and a temperature of 60 to 80 ℃;
j5) filtering the obtained extract to filter foreign matter;
j6) filtering foreign matter and adding 5 to 25 times the solvent by weight to the remaining solids to obtain an extract for 2 to 3 hours at 0.8 to 0.9 atm and a temperature of 80 to 95 ° C. for extraction;
j7) filtering the obtained extract to filter foreign matter;
j8) combining the extracts obtained by the first and second extraction and concentrating the brix ° of solids to 40 or more for 4 to 8 hours under a reduced pressure of -0.08 to -0.09 MPA at a temperature of 50 to 65 ° C; Method for producing a food for the improvement of fine dust stimulation respiratory disease characterized in that it is produced by.
상기 추출 공정에서 추출 용매로는 물, 주정, 메탄올 및 에탄올로 이루어진 군 중에서 선택되는 하나 이상인 것을 특징으로 하는 미세먼지 자극 호흡기 질환의 개선용 식품의 제조 방법.The method according to claim 2,
Extraction solvent in the extraction process is water, alcohol, methanol and ethanol is a method for producing a food for improving the fine dust stimulation respiratory disease, characterized in that at least one selected from the group consisting of.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180166310A KR102033260B1 (en) | 2018-12-20 | 2018-12-20 | Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180166310A KR102033260B1 (en) | 2018-12-20 | 2018-12-20 | Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102033260B1 true KR102033260B1 (en) | 2019-11-08 |
Family
ID=68542314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180166310A KR102033260B1 (en) | 2018-12-20 | 2018-12-20 | Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102033260B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230060553A (en) | 2021-10-27 | 2023-05-08 | 농업회사법인 주식회사 네이처포스 | Phamaceutical composition consisting of medicinal herbs extracts for preventing and treating the respiratory disease causing particulate watter in the air |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101466316B1 (en) | 2011-12-30 | 2014-12-01 | 한국생명공학연구원 | Pharmaceutical composition comprising extract or fraction of Lagerstroemia ovalifolia for prevention or treatment of inflammatory diseases or asthma |
KR101516057B1 (en) | 2012-12-07 | 2015-04-30 | 가톨릭대학교 산학협력단 | Inhalant formulation for treatment of pulmonary diseases and preparaton method thereof |
KR101582442B1 (en) * | 2015-05-26 | 2016-01-21 | 금일광선 영어조합법인 | Manufacturing method of seaweed ear processed-food and preparation thereof |
KR20180000874A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 뉴팸 | Nutritional food composition helping detoxification or elimiation of fine dust, heavy metals and antibiotics, and its manufacturing method |
-
2018
- 2018-12-20 KR KR1020180166310A patent/KR102033260B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101466316B1 (en) | 2011-12-30 | 2014-12-01 | 한국생명공학연구원 | Pharmaceutical composition comprising extract or fraction of Lagerstroemia ovalifolia for prevention or treatment of inflammatory diseases or asthma |
KR101516057B1 (en) | 2012-12-07 | 2015-04-30 | 가톨릭대학교 산학협력단 | Inhalant formulation for treatment of pulmonary diseases and preparaton method thereof |
KR101582442B1 (en) * | 2015-05-26 | 2016-01-21 | 금일광선 영어조합법인 | Manufacturing method of seaweed ear processed-food and preparation thereof |
KR20180000874A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 뉴팸 | Nutritional food composition helping detoxification or elimiation of fine dust, heavy metals and antibiotics, and its manufacturing method |
Non-Patent Citations (2)
Title |
---|
"미세먼지 씻어내는 디톡스 푸드 후코그램", 2017.2.27., 동아닷컴, <http://news.donga.com/View?gid=83084151&date=20170227> * |
"미세먼지에 황사까지 호흡 기관지에 좋은 표고버섯즙 인기!", 2018.1.18., 뉴스워커 <http://www.newsworker.co.kr/news/articleView.html?idxno=14204> * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230060553A (en) | 2021-10-27 | 2023-05-08 | 농업회사법인 주식회사 네이처포스 | Phamaceutical composition consisting of medicinal herbs extracts for preventing and treating the respiratory disease causing particulate watter in the air |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101464745B1 (en) | Compositions comprising fermentative extract of Orchidaceae for improving functions of skin | |
KR101451981B1 (en) | Compositions comprising fermentative extract of Orchidaceae for improving functions of skin | |
KR101486648B1 (en) | Fermented Sparassis crispa and method for preparing the same | |
KR101696399B1 (en) | Method for fermenting ripening object using rice straws and method for manufacturing black ballon flower roots tea using the same | |
CN105795300A (en) | Freeze-dried powder of fruit and vegetable extracts and preparation method of freeze-dried powder | |
KR101705547B1 (en) | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract | |
KR102033260B1 (en) | Food composition for improving fine dust stimulated respiratory diseases with seaweed ear extract and process for preparing the same | |
KR101770766B1 (en) | the composition comprising the specific extract isolated from Leonurus sibiricus as an active ingredient for preventing or treating respiratory inflammatory disease | |
KR101917822B1 (en) | Production method of cirsimaritin fortified thistle concentrate using Lactobacillus plantarum KCCM 11322 strain | |
CN105747236A (en) | Extract frozen-dried powder of fruit and vegetable medicine-food-homologous food and preparation method of frozen-dried powder | |
CN105707906A (en) | Probiotic medicinal and edible food extract freeze-dried powder and preparation method thereof | |
KR102124855B1 (en) | Vitamin Composition having Effect of Removing Fine Dust | |
CN105831645A (en) | Prebiotic blueberry composite powder and preparation method thereof | |
KR101768612B1 (en) | Food composition for improving liver function and method of health tea using thereof | |
KR20200094528A (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
KR101123356B1 (en) | Fermented drink produced with Lonicera japonica Thunb and the manufacturing method thereof | |
KR101259162B1 (en) | Salt using Bambusae Calulis in Liquamen and manufacturing method thereof and functional food composition | |
KR102365480B1 (en) | Manufacturing method of beverage composition for improving asthma, bronchitis or pneumonia comprising fermented extract of Aster tataricus as effective component | |
KR20140056123A (en) | The beverage containing houttuynia cordata, ficus carica, and citrus junos and the manufacturing method of it | |
KR102046654B1 (en) | Novel lactobacillus brevis omj-46 and composition for detoxificating heavy metal toxicity comprising the fermentation broth of omija manufactured by the same | |
JP2002272267A (en) | Method for artificially culturing plant worm and extracted composition of isaria japonica and functional food using the same | |
KR102389839B1 (en) | Health supplement composition for improving bronchial function including natural extracts | |
KR20070034801A (en) | Preparation of Chaga Fermented Beverage with High Hazardous Oxygen Removal Capacity | |
KR101934812B1 (en) | Process for preparing liquid tea with Geomundo sea Artemisia | |
CN113615793B (en) | Fresh-keeping method capable of keeping effective components of gastrodia elata, fresh-keeping agent and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |